Associated Papers
Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.
Zhong J et al.
Journal of Medicinal Chemistry, 2025
Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader.
Orsi DL et al.
Rsc Medicinal Chemistry, 2025
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
Wei X et al.
Cancer Letters, 2024
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G et al.
Cancers, 2024
Developing Dynamic Structure-Based Pharmacophore and ML-Trained QSAR Models for the Discovery of Novel Resistance-Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis.
Sayyah E et al.
Chemmedchem, 2024
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX et al.
Journal of Medicinal Chemistry, 2024
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I et al.
Nature Cancer, 2023
Blood Liquid Biopsy in an Advanced Medullary Thyroid Carcinoma: A Case Study with Rearranged during Transfection Heterogeneity.
Gumà J et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology, 2023
MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
Saltiki K et al.
European Journal of Endocrinology, 2022
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F et al.
Archives of Pharmacal Research, 2022
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Matrone A et al.
Frontiers in Endocrinology, 2022
Precision oncology for RET-related tumors.
Verrienti A et al.
Frontiers in Oncology, 2022
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Saha D et al.
Journal of Medicinal Chemistry, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Moccia M et al.
Scientific Reports, 2021
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.
Shen T et al.
Npj Precision Oncology, 2021
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Subbiah V et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2021
Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations.
He Y
Archiv Der Pharmazie, 2020
RET kinase alterations in targeted cancer therapy.
Liu X et al.
Cancer Drug Resistance (alhambra, Calif.), 2020
Drug resistance profiles of mutations in the RET kinase domain.
Liu X et al.
British Journal of Pharmacology, 2018